Chaudhary Khurram M, Mititelu Mihai, Lieberman Ronni M
Department of Ophthalmology, Hofstra–North Shore Long Island Jewish Medical Center, New York, New York, USA.
J Pediatr Ophthalmol Strabismus. 2013 Jan-Feb;50(1):11-9. doi: 10.3928/01913913-20120821-02. Epub 2012 Aug 28.
Vascular endothelial growth factor (VEGF) is an important factor in the pathogenesis of multiple retinal neovascular disorders. This report focuses on the quality and depth of new evidence for the use of VEGF inhibitors in selected pediatric ocular diseases, including Coats' disease, Best disease, and childhood uveitis. Because much of the literature comprises case reports and retrospective case series, the level of evidence supporting its use as a primary treatment option, or even as adjuvant therapy, is low. The standard of care is treatment of the underlying disorder to prevent neovascularization (retinal or subretinal), vitreous hemorrhage, or subsequent retinal detachment. However, these complications may not present until late in the disease course. It may then be useful to treat with these agents. Prospective studies are warranted to further elucidate the role of anti-VEGF therapy in these diseases.
血管内皮生长因子（VEGF）是多种视网膜新生血管疾病发病机制中的一个重要因素。本报告重点关注在特定儿科眼部疾病（包括科茨病、贝斯特病和儿童葡萄膜炎）中使用VEGF抑制剂的新证据的质量和深度。由于大部分文献包括病例报告和回顾性病例系列，支持将其用作主要治疗选择甚至辅助治疗的证据水平较低。标准治疗方法是治疗潜在疾病以预防新生血管形成（视网膜或视网膜下）、玻璃体出血或随后的视网膜脱离。然而，这些并发症可能直到疾病病程后期才会出现。此时使用这些药物可能会有帮助。有必要进行前瞻性研究以进一步阐明抗VEGF治疗在这些疾病中的作用。
